| Literature DB >> 15261262 |
Matthew M Morrissette1, Kenneth J Stauffer, Peter D Williams, Terry A Lyle, Joseph P Vacca, Julie A Krueger, S Dale Lewis, Bobby J Lucas, Bradley K Wong, Rebecca B White, Cynthia Miller-Stein, Elizabeth A Lyle, Audrey A Wallace, Yvonne M Leonard, Denise C Welsh, Joseph J Lynch, Daniel R McMasters.
Abstract
Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to the identification of two optimized compounds, 14 and 16.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15261262 DOI： 10.1016/j.bmcl.2004.06.030
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823